Diamyd Medical AB (publ) (DMYD-B.ST)
- Previous Close
12.02 - Open
11.80 - Bid 11.80 x --
- Ask 11.90 x --
- Day's Range
11.54 - 11.98 - 52 Week Range
6.41 - 20.00 - Volume
27,252 - Avg. Volume
263,581 - Market Cap (intraday)
1.13B - Beta (5Y Monthly) 2.07
- PE Ratio (TTM)
-- - EPS (TTM)
-1.36 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was founded in 1984 and is headquartered in Stockholm, Sweden.
www.diamyd.comRecent News: DMYD-B.ST
Performance Overview: DMYD-B.ST
Trailing total returns as of 5/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DMYD-B.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DMYD-B.ST
Valuation Measures
Market Cap
1.14B
Enterprise Value
1.00B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.72k
Price/Book (mrq)
6.30
Enterprise Value/Revenue
3.56k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.07%
Return on Equity (ttm)
-71.18%
Revenue (ttm)
282k
Net Income Avi to Common (ttm)
-120.18M
Diluted EPS (ttm)
-1.36
Balance Sheet and Cash Flow
Total Cash (mrq)
137.15M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-94.34M
Research Analysis: DMYD-B.ST
Company Insights: DMYD-B.ST
DMYD-B.ST does not have Company Insights